Arcutis Biotherapeutics Inc (NASDAQ: ARQT) on Friday, soared 18.15% from the previous trading day, before settling in for the closing price of $8.32. Within the past 52 weeks, ARQT’s price has moved between $1.76 and $13.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 303.42% over the last five years. The company achieved an average annual earnings per share of 60.14%. With a float of $101.24 million, this company’s outstanding shares have now reached $116.89 million.
The firm has a total of 296 workers. Let’s measure their productivity. In terms of profitability, gross margin is 92.17%, operating margin of -136.13%, and the pretax margin is -147.95%.
Arcutis Biotherapeutics Inc (ARQT) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Arcutis Biotherapeutics Inc is 13.39%, while institutional ownership is 99.72%. The most recent insider transaction that took place on Aug 19 ’24, was worth 14,318. In this transaction an insider of this company sold 1,728 shares at a rate of $8.29, taking the stock ownership to the 194,859 shares. Before that another transaction happened on Aug 19 ’24, when Company’s Officer proposed sale 1,728 for $8.29, making the entire transaction worth $14,318.
Arcutis Biotherapeutics Inc (ARQT) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 60.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.80% during the next five years compared to -48.07% drop over the previous five years of trading.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Arcutis Biotherapeutics Inc (ARQT) is currently performing well based on its current performance indicators. A quick ratio of 8.19 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.18, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.13 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Analysing the last 5-days average volume posted by the [Arcutis Biotherapeutics Inc, ARQT], we can find that recorded value of 2.62 million was lower than the volume posted last year of 3.7 million. As of the previous 9 days, the stock’s Stochastic %D was 33.98%. Additionally, its Average True Range was 0.77.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 45.95%, which indicates a significant decrease from 82.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 98.88% in the past 14 days, which was higher than the 79.98% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.45, while its 200-day Moving Average is $7.42. Now, the first resistance to watch is $10.51. This is followed by the second major resistance level at $11.18. The third major resistance level sits at $12.21. If the price goes on to break the first support level at $8.81, it is likely to go to the next support level at $7.78. Now, if the price goes above the second support level, the third support stands at $7.11.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
Market capitalization of the company is 1.15 billion based on 115,764K outstanding shares. Right now, sales total 59,610 K and income totals -262,140 K. The company made 30,860 K in profit during its latest quarter, and -52,330 K in sales during its previous quarter.
